Related Experiment Video
Updated: Feb 12, 2026

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
Published on: February 1, 2018
Clinical Pharmacology Considerations for Development of β Lactamase Inhibitor Combination with Antibiotics
1Zydus Research Center, Sarkhej-Bavla NH 8 A, Moraiya, Ahmedabad, 382 210, Gujarat, India.
Abstract:
The shrinking drug pipeline for antibacterial drugs has made it very precious to discover and develop novel drugs in this space. In this context, the recent approvals of β lactamase inhibitors with either cephalosporin or penem as combination drugs are welcome news to the community. There are number of β lactamase inhibitors with suggested partnered drugs that are currently in various stages of drug development. The focus of this manuscript is to provide some perspectives on clinical pharmacology considerations that may aid in the successful development of such combination drugs. In this regard, a broad framework which includes pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD guided surrogate strategies are provided to enable an informed dosing decision of the combination agent.
More Related Videos
11:27The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
Published on: April 25, 2012
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Related Concept Videos
Development of Antibiotic Resistance
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antibiotic Selection
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...